EXEL vs GMAB
Exelixis, Inc. and Genmab A/S, both Healthcare
Genmab A/S is the larger company at $16B against $13B. Over the past year EXEL returned +50% against +49% for GMAB. Ryufin's sector-relative Smart Score puts GMAB ahead, 9/10 against 8/10.
| Figure | EXEL | GMAB |
|---|---|---|
| Last close | $56.07 | $33.75 |
| Market cap | $13B | $16B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.6 | n/a |
| 1-year return | +50% | +49% |
| 5-year return | +225% | -25% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Exelixis, Inc.
Revenue of $611M in Q1 2026, net income $210M. Its largest reported line is Product Gross, 87% of the disclosed total.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.